This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
AI is now as much a part of U.S. healthcare as any other technology category in wide use across the sector. However, like no other technology, its role is “being actively shaped, not passively adopted” by clinicians and patients alike.
A recent OIG report suggested vascular surgeons, interventional cardiologists and interventional radiologists may be performing medically unnecessary procedures in office-based labs. Now, some of the leading medical societies from those fields have provided additional context.
Asking medical questions of AI with language spoken “in the wild”—meaning with LLM prompts from everyday consumers—brings back answers with decidedly mediocre accuracy, a new study shows.
The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent.
In its annual outlook report released this week, Fitch Ratings says the coming calendar year will probably strike much of the sector as “another make or break” period.